Cinven is in exclusive negotiations to acquire Nutrisens, a France-based clinical nutrition company, from Sagard MidCap. Nutrisens’ founder and CEO, Georges Devesa, along with the senior management team, is expected to reinvest significantly as part of the deal.
Financial terms have not been disclosed.
Founded in 2011, Nutrisens develops and distributes medical nutrition products aimed at treating malnutrition, dysphagia, and age-related nutritional issues. The company is headquartered in Chaponost, France, and has expanded across Europe and into Brazil, now operating in over 30 countries with more than 750 employees.
Nutrisens has grown steadily through a focus on product quality and collaboration with healthcare professionals. Its offering targets both clinical effectiveness and patient adherence.
Cinven’s investment is supported by both its French and Healthcare sector teams, who see Nutrisens as well-positioned in a growing market driven by ageing populations and increased demand for medical nutrition.
Key factors behind the deal include: A growing and resilient medical nutrition market;
Nutrisens’ scale and differentiated product portfolio; strong historical financial performance with consistent organic growth and margin improvement; and an experienced leadership team staying in place post-transaction.
The transaction is subject to regulatory approvals and customary closing conditions.
